Trial Profile
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; IRX 2 (Primary) ; Cyclophosphamide
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 30 Sep 2022 Planned primary completion date changed from 12 Oct 2022 to 5 Jul 2023.